Gilead Sciences, Inc.

Stephen E Ammann

James G Taylor

Michael Graupe

Lan Jiang

Jeromy J Cottell

Zheng-Yu Yang

Elbert Chin

Nathan E Wright

Gediminas J Brizgys

Chienhung Chou

Sheila M Zipfel

Elizabeth M Bacon

Marilyn Ndukwe

Scott D Schroeder

Daniel G Shore

Eda Y Canales

Weng K Chang

Henok H Kinfe

Scott E Lazerwith

Rhiannon Thomas-Tran

Michael L Mitchell

Devan Naduthambi

Michael R Mish

Julian Andrew Codelli

Chao-I Hung

Suzanne M Szewczyk

Marina Shatskikh

James S Cassidy

Kavoos Kolahdouzan

Christopher J Swank

Gregory F Chin

Nathan D Shapiro

Joshua J Van Veldhuizen

Yasamin Moazami

Jason K Perry

Jessica L McKinley

Xinpei Cai

Kevin X Rodriguez

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

SARS-COV2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

Pyrrolo[1,2-b] pyridazine derivatives

Thiadiazole IRAK4 compounds

Pyrrolo[1,2-B]pyridazine derivatives

Growing community of inventors

Foster City, CA, United States of America

Stephen E Ammann